Skip to main content
SpringerLink
Log in

Risk-Benefit Assessment of Anticoagulant Therapy

  • Review Article
  • Risk-Benefit Assessment
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

Thromboembolic disease is a common medical condition which, if untreated, carries a significant risk of morbidity and mortality. Treatment with anticoagulant therapy, while clearly beneficial, may expose patients to potentially serious side effects. A thoughtful risk-benefit assessment is therefore crucial before initiating therapy.

Thromboembolic disease involves syndromes of both the venous and arterial circulation, and its pathogenesis is best understood by considering the elements of Virchow’s Triad. This model defines the risk factors for venous thromboembolism and allows us to classify surgical and medical patients into low, moderate and high risk groups. Similar analysis allows risk assessment for patients prone to cardiogenic embolism resulting from nonvalvular atrial fibrillation, ischaemic heart disease, rheumatic heart disease and valvular prostheses. All anticoagulant therapy is prophylactic. Primary prophylaxis involves instituting anticoagulant therapy in patients at risk, before thromboembolism occurs, while secondary prophylaxis involves treating patients with established disease.

The 2 major anticoagulants, heparin and warfarin, differ in their mechanism of action, mode of administration and methods of monitoring. Either may be used as primary or secondary prophylaxis. Heparin, because it acts immediately, is the drug of choice for the short term treatment of thromboembolic disease. Warfarin is the drug of choice for long term oral maintenance therapy. The principal complication of heparin therapy is haemorrhage, although thrombocytopenia and osteoporosis may also occur; the complications of warfarin include haemorrhage and skin necrosis. The risks of complications vary with the underlying thromboembolic disease. After the benefits of treatment are weighed against the risks of complications, recommendations for therapy can be established.

The use of anticoagulants in pregnancy is especially complex. Here heparin is probably the preferred agent since, unlike warfarin, it does not cross the placenta and is nonteratogenic.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Ansell J. Handbook of hemostasis and thrombosis, Little, Brown and Co., Boston, 1986

    Google Scholar 

  • Ansell J, Deykin D. Heparin induced thrombocytopenia and recurrent thromboembolism. American Journal of Hematology 8: 325–332, 1980

    Article  PubMed  CAS  Google Scholar 

  • Babcock RB, Dumper CW, Scharfman WB. Heparin-induced immune thrombocytopenia. New England Journal of Medicine 295: 237–241, 1976

    Article  PubMed  CAS  Google Scholar 

  • Babikian VL, Kase CS, Pessin MS, Norrving B, Gorelick PB. Intracerebral haemorrhage in stroke patients anticoagulated with heparin. Stroke 20: 1500–1503 1989

    Article  PubMed  CAS  Google Scholar 

  • Becker CG. Oral anticoagulant therapy and skin necrosis: speculations on pathogenesis. Advances in Experimental Medicine and Biology 214: 217–222, 1987

    PubMed  CAS  Google Scholar 

  • Bounameaux H, Verhaeghe R, Verstraete M. Thromboembolism and antithrombotic therapy in peripheral arterial disease. Journal of the American College of Cardiology 8: 98B–103B, 1986

    Article  PubMed  CAS  Google Scholar 

  • Breddin HK. Thrombosis and Virchow’s triad: what is established? Seminars in Thrombosis and Hemostasis 15: 237–239, 1989

    Article  PubMed  CAS  Google Scholar 

  • Caprini JA, Natonson RA. Postoperative deep vein thrombosis: current clinical considerations. Seminars in Thrombosis and Hemostasis 15: 244–249, 1989

    Article  PubMed  CAS  Google Scholar 

  • Cerebral Embolism Study Group. Cardioembolic stroke, early anticoagulation, and brain haemorrhage. Archives of Internal Medicine 147: 636–640, 1987

    Article  Google Scholar 

  • Cerebral Embolism Task Force. Cardiogenic brain embolism: the second report of the Cerebral Embolism Task Force. Archives of Neurology 46: 727–743, 1989

    Article  Google Scholar 

  • Chesebro JH, Adams PC, Fuster V. Antithrombotic therapy in patients with valvular heart disease and prosthetic heart valves. Journal of the American College of Cardiology 8: 41B–56B, 1986

    Article  PubMed  CAS  Google Scholar 

  • Clagett GP, Genton E, Salzman EW. Antithrombotic therapy in peripheral vascular disease. Chest 95: 128S–139S, 1989

    PubMed  CAS  Google Scholar 

  • Cola C, Ansell J. Heparin-induced thrombocytopenia and arterial thrombosis: alternative therapies. American Heart Journal 119: 368–374, 1990

    Article  PubMed  CAS  Google Scholar 

  • Cole MS, Minifee PK, Wolma FJ. Coumarin necrosis —a review of the literature. Surgery 103: 271–277, 1988

    PubMed  CAS  Google Scholar 

  • Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopedic, and urologic surgery. New England Journal of Medicine 318: 1162–1173, 1988

    Article  PubMed  CAS  Google Scholar 

  • Consensus Conference. Prevention of venous thrombosis and pulmonary embolism. Journal of the American Medical Association 256: 744–749, 1986

    Article  Google Scholar 

  • Dalen JE. Valvular heart disease, infected valves and prosthetic heart valves. American Journal of Cardiology 65: 29C–31C, 1990

    Article  PubMed  CAS  Google Scholar 

  • Dalen JE, Alpert JS. Natural history of pulmonary embolism. Progress in Cardiovascular Diseases 17: 259–270, 1975

    Article  PubMed  CAS  Google Scholar 

  • Dalen JE, Paraskos JA, Ockene IS, Alpert JS, Hirsh J. Venous thromboembolism: scope of the problem. Chest 89: 370S–373S, 1986

    PubMed  CAS  Google Scholar 

  • D’Angelo SV, Comp PC, Esmon CT, D’Angelo A. Relationship between protein C antigen and anticoagulant activity during oral anticoagulation and in selected disease states. Journal of Clinical Investigation 77: 416–425, 1986

    Article  PubMed  Google Scholar 

  • Dunn M, Alexander J, deSilva R, Hildner F. Antithrombotic therapy in atrial fibrillation. Chest 95: 118S–127S, 1989

    Article  PubMed  CAS  Google Scholar 

  • Errichetti AM, Holden A, Ansell J. Management of oral anticoagulant therapy: experience with an anticoagulation clinic. Archives of Internal Medicine 144: 1966–1968, 1984

    Article  PubMed  CAS  Google Scholar 

  • Forfar JC. A 7-year analysis of haemorrhage in patients on long-term anticoagulant treatment. British Heart Journal 42: 128–132, 1979

    Article  PubMed  CAS  Google Scholar 

  • Frame JN, Mulvey KP, Phares JC, Andersen MJ. Correction of severe heparin-associated thrombocytopenia with intravenous immunoglobulin. Annals of Internal Medicine 111: 946–947, 1989

    PubMed  CAS  Google Scholar 

  • Fuster V, Badimon L, Badimon JJ, Chesebro J. Prevention of thromboembolism induced by prosthetic heart valves. Seminars in Thrombosis and Hemostasis 14: 50–58, 1988

    Article  PubMed  CAS  Google Scholar 

  • Fuster V, Halperin JL. Left ventricular thrombi and cerebral embolism. New England Journal of Medicine 320: 392–394, 1989

    Article  PubMed  CAS  Google Scholar 

  • Giannuzzi P, Imparato A, Temporelli PL, Santoto F, Tavazzi L. Left ventricular thrombosis is frequent and systemic embolization rare in anterior myocardial infarction. Abstract 1368. European Heart Journal 10: 264, 1989

    Google Scholar 

  • Ginsberg JS, Hirsh J. Anticoagulants during pregnancy. Annual Review of Medicine 40: 79–86, 1989a

    Article  PubMed  CAS  Google Scholar 

  • Ginsberg JS, Hirsh J. Use of anticoagulants during pregnancy. Chest 95: 156S–160S, 1989b

    PubMed  CAS  Google Scholar 

  • Gordis L. The virtual disappearance of rheumatic fever in the United States: lessons in the rise and fall of disease. Circulation 72: 1155–1162, 1985

    Article  PubMed  CAS  Google Scholar 

  • Gurwitz JM, Goldberg RJ, Holden A, Knapic N, Ansell J. Age-related risks of long-term oral anticoagulant therapy. Archives of Internal Medicine 148: 1733–1736, 1988

    Article  PubMed  CAS  Google Scholar 

  • Halperin JL, Hart RG. Atrial fibrillation and stroke: new ideas, persisting dilemmas. Stroke 19: 937–941, 1988

    Article  PubMed  CAS  Google Scholar 

  • Harker L. Clinical trials evaluating platelet modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis. Circulation 73: 206–223, 1986

    Article  PubMed  CAS  Google Scholar 

  • Hirsh J. Mechanism of action and monitoring of anticoagulants. Seminars in Thrombosis and Hemostasis 12: 1–11, 1986

    Article  PubMed  CAS  Google Scholar 

  • Hirsh J. Is the dose of warfarin prescribed by American physicians unnecessarily high? Archives of Internal Medicine 147: 769–771, 1987

    Article  PubMed  CAS  Google Scholar 

  • Hirsh J, Hull RD. Natural history and clinical features of venous thrombosis. In Colman et al. (Eds) Hemostasis and thrombosis: basic principles and clinical practice, 2nd ed., pp. 1208–1219, J.B. Lippincott Co., Philadelphia, 1987a

    Google Scholar 

  • Hirsh J, Hull RD. Venous thromboembolism: scope of the problem and strategies for prevention and management. In Hirsh & Hull (Eds) Venous thromboembolism: natural history, diagnosis, and management, pp. 1–4, CRC Press, Boca Raton, 1987b

    Google Scholar 

  • Hirsh J, Hull RD. Pathogenesis of venous thromboembolism and clinical risk factors. In Hirsh & Hull (Eds) Venous thromboembolism: natural history, diagnosis, and management, pp. 5–16, CRC Press, Boca Raton, 1987c

    Google Scholar 

  • Hirsh J. Hull RD. A practical approach to the prophylaxis of venous thromboembolism. In Hirsh & Hull (Eds) Venous thromboembolism: natural history, diagnosis and management, pp. 117–129, CRC Press, Boca Raton, 1987d

    Google Scholar 

  • Hirsh J, Hull RD. Management of venous thromboembolism during pregnancy. In Hirsh & Hull (Eds) Venous thromboembolism: natural history, diagnosis, and management, pp. 145–152, CRC Press, Boca Raton, 1987e

    Google Scholar 

  • Hirsh J, Hull RD, Raskob GE. Epidemiology and pathogenesis of venous thrombosis. Journal of the American College of Cardiology 8: 104B–113B, 1986

    Article  PubMed  CAS  Google Scholar 

  • Hirsh J, Levine MN. The optimal intensity of oral anticoagulant therapy. Journal of the American Medical Association 258: 2723–2726, 1987

    Article  PubMed  CAS  Google Scholar 

  • Hirsh J, Poller L, Deykin D, Levine M, Dalen JE. Optimal therapeutic range for oral anticoagulants. Chest 95: 5S–11S, 1989

    PubMed  CAS  Google Scholar 

  • Hull R, Hirsh J, Jay R, Carter C, England C, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. New England Journal of Medicine 307: 1676–1681, 1982

    Article  PubMed  CAS  Google Scholar 

  • Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest 95: 37S–51S, 1989

    PubMed  CAS  Google Scholar 

  • Jaffin BW, Bliss CM, Lamont JT. Significance of occult gastrointestinal bleeding during anticoagulation therapy. American Journal of Medicine 83: 269–272, 1987

    Article  PubMed  CAS  Google Scholar 

  • Kakker V. Prevention of venous thrombosis and pulmonary embolism. American Journal of Cardiology 65: 50C–54C, 1990

    Article  Google Scholar 

  • Kakkar VV. Prevention of venous thromboembolism. In Bloom et al. (Eds) Haemostasis and thrombosis, 2nd ed pp. 802–819, Churchill Livingstone, London, 1987

    Google Scholar 

  • Kannel WB, Abbott RD, Savage DD, McNamara PM. Coronary heart disease and atrial fibrillation: the Framingham study. American Heart Journal 106: 389–396, 1983

    Article  PubMed  CAS  Google Scholar 

  • Kaplan K. Prophylactic anticoagulation following acute myocardial infarction. Archives of Internal Medicine 146: 593–597, 1986

    Article  PubMed  CAS  Google Scholar 

  • Kempster PA, Gerraty RP, Gates PC. Asymptomatic cerebral infarction in patients with chronic atrial fibrillation. Stroke 19: 955–957, 1988

    Article  PubMed  CAS  Google Scholar 

  • Kirkwood TBL. Calibration of reference thromboplastins and standardization of the prothrombin time ratio. Thrombosis and Hemostasis 49: 238–244, 1983

    CAS  Google Scholar 

  • Kitchens CS. Concept of hypercoagulability: a review of its development, clinical application, and recent progress. Seminars in Thrombosis and Hemostasis 11: 293–315, 1985

    Article  PubMed  CAS  Google Scholar 

  • Kramer RJ, Zeldis SM, Hamby RI. Atrial fibrillation —a marker for abnormal left ventricular function in coronary heart disease. British Heart Journal 47: 606–608, 1982

    Article  PubMed  CAS  Google Scholar 

  • Krauth D, Holden A, Knapic N, Liepman M, Ansell J. Safety and efficacy of long-term oral anticoagulation in cancer patients. Cancer 59: 983–985, 1987

    Article  PubMed  CAS  Google Scholar 

  • Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L. Identification and preliminary validation of predictors of major bleeding in hospitalised patients starting anticoagulant therapy. American Journal of Medicine 82: 703–713, 1987

    Article  PubMed  CAS  Google Scholar 

  • Levine HJ, Pauker SG, Salzman EW. Antithrombotic therapy in valvular heart disease. Chest 95: 98S–106S, 1989

    PubMed  CAS  Google Scholar 

  • Levine MN, Raskob G, Hirsh J. Hemorrhagic complications of long-term anticoagulant therapy. Chest 95: 26S–36S, 1989

    PubMed  CAS  Google Scholar 

  • Marder VJ, Sherry S. Thrombolytic therapy: current status. New England Journal of Medicine 318: 1512–1520, 1585–1595, 1988

    Article  PubMed  CAS  Google Scholar 

  • Massell BF, Chute CG, Walker AM, Kurland GS. Penicillin and the marked decrease in morbidity and mortality from rheumatic fever in the United States. New England Journal of Medicine 318: 280–286, 1988

    Article  PubMed  CAS  Google Scholar 

  • Mazanec DJ, Grisanti JM. Drug-induced osteoporosis. Cleveland Clinical Journal of Medicine 56: 297–303, 1989

    CAS  Google Scholar 

  • Mehta JL, Kitchens CS. Pharmacology of platelet-inhibitory drugs, anticoagulants, and thrombolytic agents. Cardiovascular Clinics 18: 163–179, 1987

    PubMed  CAS  Google Scholar 

  • Meltzer RS, Visser CA, Fuster V. Intracardiac thrombi and systemic embolisation. Annals of Internal Medicine 104: 689–698, 1986

    PubMed  CAS  Google Scholar 

  • Miller ML. Heparin-induced thrombocytopenia. Cleveland Clinic Journal of Medicine 56: 483–490, 1989

    PubMed  CAS  Google Scholar 

  • Nelson PH, Moser KM, Stoner C, Moser KS. Risk of complications during intravenous heparin therapy. Western Journal of Medicine 136: 189–197, 1982

    PubMed  CAS  Google Scholar 

  • Ofosu FA, Gary E. Mechanisms of action of heparin: applications to the development of derivatives of heparin and heparinoids with antithrombotic properties. Seminars in Thrombosis and Hemostasis 14: 9–17, 1988

    Article  PubMed  CAS  Google Scholar 

  • Petersen P. Thromboembolic complications of atrial fibrillation and their prevention: a review. American Journal of Cardiology 65: 24C–28C, 1990

    Article  PubMed  CAS  Google Scholar 

  • Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK Study. Lancet 1: 175–179, 1989

    Article  PubMed  CAS  Google Scholar 

  • Petersen P, Kastrup J, Helweg-Larsen S, Boysen G, Godtfredsen J. Risk factors for thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK Study. Archives of Internal Medicine 150: 819–821, 1990

    Article  PubMed  CAS  Google Scholar 

  • Petersen P, Madsen EB, Brun B, Pedersen F, Glydensted C, et al. Silent cerebral infarction in chronic atrial fibrillation. Stroke 18: 1098–1100, 1987

    Article  PubMed  CAS  Google Scholar 

  • Peterson CE, Kwaan HC. Current concepts of warfarin therapy. Archives of Internal Medicine 146: 581–584, 1986

    Article  PubMed  CAS  Google Scholar 

  • Petty GW, Lennihan L, Mohr JP, Mauser WA, Weitz J, et al. Complications of long-term anticoagulation. Annals of Neurology 23: 570–574, 1988

    Article  PubMed  CAS  Google Scholar 

  • Powers PJ, Gent M, Jay RM, Julian DH, Turpie AGG, et al. A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip. Archives of Internal Medicine 149: 771–774, 1989

    Article  PubMed  CAS  Google Scholar 

  • Resnekov L, Chediak J, Hirsh J, Lewis HD. Antithfombotic agents in coronary artery disease. Chest 95: 52S–72S, 1989

    PubMed  CAS  Google Scholar 

  • Roy D, Marchand E, Gagne P, Chabot M, Cartier R. Usefulness of anticoagulant therapy in the prevention of embolie complications of atrial fibrillation. American Heart Journal 112: 1039–1043, 1986

    Article  PubMed  CAS  Google Scholar 

  • Saour JN, Sieck JO, Mamo LAR, Gallus AS. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. New England Journal of Medicine 322: 428–432, 1990

    Article  PubMed  CAS  Google Scholar 

  • Schafer AI. The hypercoagulable states. Annals of Internal Medicine 102: 814–828, 1985

    PubMed  CAS  Google Scholar 

  • Scott AK. Warfarin usage: can safety be improved? Pharmacology and Therapeutics 42: 429–457, 1989

    Article  PubMed  CAS  Google Scholar 

  • Sherman DG. Cardiac embolism: The neurologist’s perspective. American Journal of Cardiology 65: 32C–37C, 1990

    Article  PubMed  CAS  Google Scholar 

  • Sherman DG, Dyken ML, Fisher M, Harrison MJG, Hart RG. Antithrombotic therapy for cerebrovascular disorders. Chest 95: 140S–155S, 1989

    PubMed  CAS  Google Scholar 

  • Sherman DG, Hart RG. Thromboembolism and antithrombotic therapy in cerebrovascular disease. Journal of the American College of Cardiology 8: 88B–97B, 1986

    Article  PubMed  CAS  Google Scholar 

  • Stein B, Fuster V. Antithrombotic therapy in acute myocardial infarction: prevention of venous, left ventricular and coronary artery thromboembolism. American Journal of Cardiology 64: 33B–40B, 1989

    Article  PubMed  CAS  Google Scholar 

  • Stein PD, Kantrowitz A. Antithrombotic therapy in mechanical and biological prosthetic heart valves and saphenous vein bypass grafts. Chest 95: 107S–117S, 1989

    Article  PubMed  CAS  Google Scholar 

  • Stroke Prevention in Atrial Fibrillation Study Group Investigators. Preliminary report of the stroke prevention in atrial fibrillation study. New England Journal of Medicine 322: 863–868, 1990

    Google Scholar 

  • Tabibian N. Acute gastrointestinal bleeding in anticoagulated patients: a prospective evaluation. American Journal of Gastroenterology 84: 10–12, 1989

    PubMed  CAS  Google Scholar 

  • Thomas DP. Overview of venous thrombogenesis. Seminars in Thrombosis and Hemostasis 14: 1–8, 1988

    Article  PubMed  CAS  Google Scholar 

  • Turpie AGG. Anticoagulant therapy after acute myocardial infarction. American Journal of Cardiology 65: 20C–23C, 1990

    Article  PubMed  CAS  Google Scholar 

  • Turpie AGG, Gunstensen J, Hirsh J, Nelson H, Gent M. Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet 1: 1242–1245, 1988

    Article  PubMed  CAS  Google Scholar 

  • Turpie AGG, Robinson JG, Doyle DJ, Mulji AS, Mishkel GJ, et al. Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. New England Journal of Medicine 320: 352–357, 1989

    Article  PubMed  CAS  Google Scholar 

  • Warkentin TE, Kelton JG. Heparin-induced thrombocytopenia. Annual Review in Medicine 40: 31–44, 1989

    Article  CAS  Google Scholar 

  • Wessler S, Gitel SN. Pharmacology of heparin and warfarin. Journal of the American College of Cardiology 8: 10B–20B, 1986

    Article  PubMed  CAS  Google Scholar 

  • Wessler S, Gitel SN. Warfarin. From bedside to bench. New England Journal of Medicine 311: 645–652, 1984

    Article  PubMed  CAS  Google Scholar 

  • Wolf PA, Dawber TR, Thomas HE, Kannel WB. Epidemiologie assessment of chronic atrial fibrillation and risk of stroke: the Framingham Study. Neurology 28: 973–977, 1978

    Article  PubMed  CAS  Google Scholar 

  • Wolf PA, Kannel WB, McGee DL, Meeks SL, Bharucha NE, et al. Duration of atrial fibrillation and imminence of stroke: the Framingham Study. Stroke 14: 664–667, 1983

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Massachusetts Medical Center, 55 Lake Avenue North, Worcester, Massachusetts, 01655, USA

    Robert Harrington &  Jack Ansell

Authors
  1. Robert Harrington
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jack Ansell
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Harrington, R., Ansell, J. Risk-Benefit Assessment of Anticoagulant Therapy. Drug-Safety 6, 54–69 (1991). https://doi.org/10.2165/00002018-199106010-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199106010-00006

Keywords

Search

Navigation